Cerus Corporation is an American multinational biotechnology company headquartered in Concord, California that develops and provides a treatment system to pathogen-reduce human blood products for the healthcare industry.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| CERS | CERUS CORP | 2026-04-02 18:12:15 | 1.83 | -0.03 | -1.61 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CERS | 0001020214 | CERUS CORP | US1570851014 | 254900BIEY9XIDA04Q21 | 680262011 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 1220 CONCORD AVENUE | CONCORD | CA | 94520 | UNITED STATES | US | 9252886000 | 1220 CONCORD AVENUE, CONCORD, CA, 94520 | 1220 CONCORD AVENUE, CONCORD, CA, 94520 | — | Biotechnology | 1991 | — | 254 | https://www.cerus.com | 230,000,000 | 192,142,000 | 192,171,776 | Cerus Corporation is an American multinational biotechnology company headquartered in Concord, California that develops and provides a treatment system to pathogen-reduce human blood products for the healthcare industry. | 2026-04-02 18:17:28 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 230,000,000 | -10,000,000 | -4.1667 | 192,171,776 | 6,381,961 | 3.435 |
| 2024 | 240,000,000 | -133,000,000 | -35.6568 | 185,789,815 | 4,507,090 | 2.4862 |
| 2023 | 373,000,000 | -533,000,000 | -58.83 | 181,282,725 | 3,664,853 | 2.0633 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Vivek Jayaraman | Chief Operating Officer | 2024 | 548,402 | 60,324 | 872,000 | 0 | 3,142 | 1,483,868 |
| Richard Benjamin | Chief Medical Officer | 2024 | 493,077 | 44,377 | 588,600 | 0 | 3,564 | 1,129,618 |
| William M. Greenman | Chief Executive Officer, President | 2024 | 770,000 | 110,495 | 2,092,800 | 0 | 2,322 | 2,975,617 |
| Kevin D. Green | Chief Financial Officer, Vice President | 2024 | 488,119 | 53,693 | 725,940 | 0 | 1,242 | 1,268,994 |
| Chrystal Jensen | Chief Legal Officer, Secretary, General Counsel | 2024 | 468,530 | 46,384 | 588,600 | 0 | 1,242 | 1,104,756 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 275 |
| 2024 | 281 |
| 2023 | 288 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 233,798,000 | 201,321,000 | 186,797,000 |
| Cost Of Revenue | 93,845,000 | 80,748,000 | 69,967,000 |
| Gross Profit | 112,288,000 | 99,522,000 | 86,400,000 |
| Research And Development Expenses | 67,720,000 | 58,907,000 | 67,639,000 |
| General And Administrative Expenses | 80,914,000 | 75,891,000 | 75,516,000 |
| Operating Expenses | 148,634,000 | 134,798,000 | 146,883,000 |
| Operating Income | -8,681,000 | -14,225,000 | -30,053,000 |
| Net Income | -15,627,000 | -20,918,000 | -37,489,000 |
| Earnings Per Share Basic | -0.08 | -0.11 | -0.21 |
| Earnings Per Share Diluted | -0.08 | -0.11 | -0.21 |
| Weighted Average Shares Outstanding Basic | 190,594,000 | 184,563,000 | 180,270,000 |
| Weighted Average Shares Outstanding Diluted | 190,594,000 | 184,563,000 | 180,270,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 19,961,000 | 20,266,000 | 11,647,000 |
| Marketable Securities Current | 62,918,000 | 60,186,000 | 54,205,000 |
| Accounts Receivable | 30,374,000 | 29,777,000 | 35,500,000 |
| Inventories | 56,101,000 | 38,150,000 | 39,868,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 174,384,000 | 152,022,000 | 144,441,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 9,204,000 | 7,154,000 | 8,640,000 |
| Other Assets Non Current | 11,049,000 | 16,801,000 | 11,425,000 |
| Total Assets Non Current | 9,204,000 | 7,154,000 | 8,640,000 |
| Total Assets | 221,859,000 | 200,917,000 | 197,748,000 |
| Accounts Payable | 28,008,000 | 21,695,000 | 23,842,000 |
| Deferred Revenue | 1,274,000 | 1,398,000 | 2,002,000 |
| Short Term Debt | 43,343,000 | 19,297,000 | 20,000,000 |
| Other Liabilities Current | 25,271,000 | 18,943,000 | 19,225,000 |
| Total Liabilities Current | 100,801,000 | 63,608,000 | 67,521,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 5,395,000 | 3,888,000 | 3,236,000 |
| Total Liabilities Non Current | 56,093,000 | 80,413,000 | 76,783,000 |
| Total Liabilities | 156,894,000 | 144,021,000 | 144,304,000 |
| Common Stock | 192,000 | 186,000 | 181,000 |
| Retained Earnings | -1,081,155,000 | -1,065,528,000 | -1,044,610,000 |
| Accumulated Other Comprehensive Income | -156,000 | -400,000 | -1,274,000 |
| Total Shareholders Equity | 64,224,000 | 56,145,000 | 52,650,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 2,000,000 | 2,000,000 | 2,400,000 |
| Share Based Compensation Expense | 22,867,000 | 22,867,000 | 20,271,000 |
| Other Non Cash Income Expense | — | — | 0 |
| Change In Accounts Receivable | 396,000 | -5,504,000 | 1,102,000 |
| Change In Inventories | 14,682,000 | -7,030,000 | 14,947,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 5,725,000 | -1,477,000 | -7,335,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 4,837,000 | 11,359,000 | -43,168,000 |
| Purchases Of Marketable Securities | 42,777,000 | 42,975,000 | 2,486,000 |
| Sales Of Marketable Securities | 40,341,000 | 37,682,000 | 15,707,000 |
| Acquisition Of Property Plant And Equipment | 3,729,000 | 2,837,000 | 4,597,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -6,165,000 | -8,130,000 | 8,624,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | -35,000 | -137,000 | -175,000 |
| Repurchase Of Common Stock | 1,000,000 | 1,000,000 | 1,000,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 595,000 | 804,000 | 925,000 |
| Cash From Financing Activities | 231,000 | 4,964,000 | 10,673,000 |
| Change In Cash | -761,000 | 8,002,000 | -23,999,000 |
| Cash At End Of Period | 19,961,000 | 20,266,000 | 11,647,000 |
| Income Taxes Paid | 301,000 | 356,000 | 322,000 |
| Interest Paid | 8,521,000 | 9,295,000 | 9,210,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.08 | -0.11 | -0.21 |
| Price To Earnings Ratio | -25.75 | -14 | -10.2857 |
| Earnings Growth Rate | -27.2727 | -47.619 | -12.5 |
| Price Earnings To Growth Ratio | 0.9442 | 0.294 | 0.8229 |
| Book Value Per Share | 0.3409 | 0.3083 | 0.2965 |
| Price To Book Ratio | 6.0436 | 4.9956 | 7.2858 |
| Ebitda | -4,983,000 | -9,685,000 | -26,381,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 4,050,000 | 514,000 | 71,000 |
| Free Cash Flow | 787,000 | 10,845,000 | -43,239,000 |
| Return On Equity | -0.2433 | -0.3726 | -0.712 |
| One Year Beta | 1.627 | 2.0692 | 2.2087 |
| Three Year Beta | 1.8589 | 1.8472 | 1.7619 |
| Five Year Beta | 1.7571 | 1.4332 | 1.3819 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Jensen Chrystal | Chief Legal Officer | 2026-04-01 | 200,000 | A | 1,146,131 |
| Green Kevin Dennis | Chief Financial Officer | 2026-04-01 | 200,000 | A | 1,240,551 |
| Benjamin Richard J | Chief Medical Officer | 2026-03-12 | 101,740 | D | 777,361 |
| Green Kevin Dennis | Chief Financial Officer | 2026-03-12 | 127,544 | D | 1,040,551 |
| Greenman William Mariner | Director, President and CEO | 2026-03-12 | 447,757 | D | 4,998,493 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| BURKETT FINANCIAL SERVICES, LLC | 2026-03-31 | 4,449 | 2,445 | 1.8196 |
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 4,960,018 | 2,407,776 | 2.06 |
| HSBC HOLDINGS PLC | 2025-12-31 | 421,099 | 203,922 | 2.065 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 25,896 | 12,571 | 2.06 |
| Corient Private Wealth LLC | 2025-12-31 | 20,885 | 10,138 | 2.0601 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Global X Funds | 2026-01-31 | Global X Russell 2000 ETF | RSSL | 83,471 | 194,487.43 | 0.014 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 191,505 | 446,206.65 | 0.0167 |
| PRIMECAP Odyssey Funds | 2026-01-31 | PRIMECAP Odyssey Aggressive Growth Fund | POAGX | 794,500 | 1,851,185 | 0.0268 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Class P Shares | GMAPX | 211,071 | 491,795.43 | 0.0832 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Class R6 Shares | GCSUX | 211,071 | 491,795.43 | 0.0832 |